Drugs / tTF-NGR
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02902237 | Mar 2017 → Nov 2019 | cancer, lymphoma | University Hospital Muenster | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05597917 | Oct 2021 → Aug 2026 overdue | soft tissue sarcoma | University of Münster | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tTF-NGR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02902237 ↗ |
| Known as | truncated tissue factor (tTF)-NGR | “truncated tissue factor (tTF)-NGR” NCT02902237 ↗ |
| Modality | Protein / enzyme biologic | “Truncated tissue factor (tTF) with a C-terminal NGR-peptide (tTF-NGR) binds to CD13 and causes tumor vascular thrombosis with infarction.” PMID 32517329 ↗ Jun 2020 |
| Route | Intravenous | “treated intravenously (iv) with increasing doses of tTF-NGR” NCT02902237 ↗ |